Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 7;16(8):1660–1670. doi: 10.4103/1673-5374.303045

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2021 Neural Regeneration Research

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

PMC Copyright notice

Effects of exendin-4 and DA-CH5 on mitogenesis-related protein expression in 6-OHDA-treated SH-SY5Y cells.

Cells were treated with 350 µM of 6-OHDA with or without 100 nM of exendin-4 or DA-CH5 for 24 hours. (A) Bands of mitogenesis-related proteins. GAPDH was used as the loading control. (B, C) Quantitative results of PGC-1α (B) and NRF-1 (C) expression. All data are represented as the mean ± SD of quadruplicate independent experiments. *P < 0.001, vs. control group (CON); †P < 0.05, †††P < 0.001, vs. 6-OHDA group; §P < 0.05, vs. 6-OHDA + exendin-4 group (one-way analysis of variance followed by Tukey’s multiple comparison test). 6-OHDA: 6-Hydroxydopamine; exendin-4 and DA-CH5: glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; NRF-1: nuclear respiratory factor 1; PD: Parkinson’s disease; PGC-1α: proliferator-activated receptor-gamma coactivator 1α.